AI News, Latest news about big data artificial intelligence
Stories of AI Failure and How to Avoid Similar AI Fails
This article includes stories of recent, high-profile AI fails, as well as information and advice on how to avoid your own AI failure: Full disclosure if you’re new to Lexalytics: we provide a software platform that uses AI and machine learning to help people analyze text documents, including tweets, reviews and contracts.
The first line of the press release boldly declares, “MD Anderson is using the IBM Watson cognitive computing system for its mission to eradicate cancer.”
IBM’s role was to enable clinicians to “uncover valuable insights from the cancer center’s rich patient and research databases.”
In July 2018, StatNews reviewed internal IBM documents and found that IBM’s Watson was making erroneous, downright dangerous cancer treatment advice.
including one case where Watson suggested that doctors give a cancer patient with severe bleeding a drug that could worsen the bleeding.
The phone’s shiniest new feature was Face ID, a facial recognition system that replaced the fingerprint reader as your primary passcode.
Apple said that Face ID used the the iPhone X’s advanced front-facing camera and machine learning to create a 3-dimensional map of your face.
The machine learning/AI component helped the system adapt to cosmetic changes (such as putting on make-up, donning a pair of glasses, or wrapping a scarf around your neck), without compromising on security.
But a week after the iPhone X’s launch, hackers were already claiming to beat Face ID using 3D printed masks. Vietnam-based security firm Bkav found that they could successfully unlock a Face ID-equipped iPhone by glueing 2D “eyes”
Bkav’s claims, outlined in a blog post, gained widespread attention, not least because Apple had already written that Face ID was designed to protect against “spoofing by masks or other techniques”
As one Amazon engineer told The Guardian in 2018, “They literally wanted it to be an engine where I’m going to give you 100 résumés, it will spit out the top five, and we’ll hire those.” But eventually, the Amazon engineers realized that they’d taught their own AI that male candidates were automatically better.
In 2018, the American Civil Liberties Union showed how Amazon’s AI-based Rekognition facial recognition system According to the ACLU, “Nearly 40 percent of Rekognition’s false matches in our test were of people of color, even though they make up only 20 percent of Congress.” In fact, that’s not even the first time someone’s proven that Rekognition is racially biased.
In another study, University of Toronto and MIT researchers found that every facial recognition system they tested performed better on lighter-skinned faces.
Seriously, just read this article from The Guardian: How white engineers built racist code – and why it’s dangerous for black people Microsoft and Apple aren’t the only companies who’ve made headlines with embarrassing AI fails.
Together, these 5 AI failures cover: chatbots, political gaffs, autonomous driving accidents, facial recognition mixups, and angry neighbors.
In the rush to stay ahead of the technology curve, companies often fail to consider the impact of their inherent biases.
This is particularly dangerous for companies working in data analytics for healthcare, biotechnology, financial services and law.
Just look at Watson for Oncology: data bias and lack of social context doomed that AI project to failure and sent $62 million down the drain.
As cars become more complex, insurance companies advise owners to keep up with preventative maintenance before the cost of repairs becomes staggering.
In this article on Forbes, he examines a number of business applications for AI solutions to: “Building a business case for AI isn’t so different from building one for any other business problem,”
Jeff puts it best: “With the right business case and the right data, AI can deliver powerful time and cost savings, as well as valuable insights you can use to improve your business.”
Delivering Precision Medicine's True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics
Predictive Oncology (NASDAQ: POAI) (POAI Profile) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer.
However, the scientific community has come to realize, due to low success rates in these applications, that genomic data itself — utilizing a just-genomics approach — doesn't fully address the complexities of cancer and is merely scratching the surface of personalized medicine's true potential.
The multi-omic approach (genome, transcriptome, epigenome, proteome, responseome and microbiome) provides researchers and clinicians the comprehensive information and interactions necessary for new drug development and treating each patient's unique cancer in the most effective method possible.
Market Potential Major players in the space are looking to get their hands on comprehensive, multi-omic data sets that can help them not only understand the type of cancer a patient may have but also strongly predict which therapies will be most effective in fighting each specific cancer.
Unfortunately, such data is fragmented and scarce, and the initiation of such data collecting is costly and time consuming. Predictive Oncology (NASDAQ: POAI) has already assembled one of the largest databases of drug-response and outcome data in the world. Indicating market trajectory, the precision medicine market is projected to explode to more than $96 billion within the next five years.
By contrast, companies beginning to collect and analyze data must wait to discover how patients' tumors will initially respond to prescribed therapies and to evaluate patient outcomes, a process that takes approximately five years.
This partnership aims to accelerate the development of next-generation functional genomics technologies and build on the databases GSK currently has available from human genetics. AstraZeneca (NYSE: AZN), a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, is utilizing precision medicine in the most prevalent and deadly tumor types.
AZN is concentrating on biomarker-driven indications to dramatically improve five-year survival in five tumor types, including ovarian cancer and non-small cell lung cancer. Senior vice president of Precision Medicine at AstraZeneca Ruth March notes that the greatest advance of personalized healthcare in oncology has been the realization that some tumors are driven by individual genes.
Discovering which genes cause certain types of tumors enables scientists to develop a medicine that's best for that tumor, and then select patients that are best for that medicine. Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
The company continues to gain new insights using sophisticated, proven and emerging technologies. With very lives at stake, it's little wonder that key players in the pharma sector have shifted focus to precision medicine, a powerhouse combination of rich, historical patient data and powerful AI platforms.
About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime.
As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public.
NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
Home - WSU AI, Big Data, Analytics Group
While we have reached an all-time high in terms of AI’s rate of advance, funding and enthusiasm, there is still a wide gap between sci-fi expectations and the realities of what can be accomplished by machines today.
It is because it is developing quite fast and we have achieved some major milestones in recent years that have contributed to the interest (e.g., speech recognition, language translation, game play, computer vision, and chat bots) and free human hands from repetitive tasks.
Artificial Intelligence For The World's Most Demanding Industries
Our systems utilize a unique hybrid approach, combining the best of conventional numeric AI approaches and the best of higher order symbolic AI techniques to deliver cognitive reasoning and intelligence that emulates human intuition.